Table 1.
Distributions of subgroups, comparators and treatment efficacy
| Subgroup | Proportion (%) | Cirrhotic (%) | Currently recommended treatment | SVR (cirrhotic/noncirrhotic) | Source | Sofosbuvir | SVR (cirrhotic/non cirrhotic) | Source |
|---|---|---|---|---|---|---|---|---|
| G1 naive | 56.8 | 40.0 | Télaprévir + PEGINF + RBV (48W) | 75.4/61.0 | Jacobson et al. 2011 [12] | SOF + PEGINF + RBV (12W) | 91.3/80.8 | Lalezary et al. 2013 [33] |
| G1 naive coinfected | 4.3 | 40.0 | Télaprévir + PEGINF + RBV (48W) | 72.1/61.0 | Sulkowski et al. AASLD 2012 | SOF + PEGINF + RBV (12W) | 77.1/60.0 | Sulkowski et al. 2013 [36] |
| G2 naive | 3.1 | 40.0 | PEGINF+RBV (24W) | 81.5/61.5 | Lawitz et al. 2013 [21] | SOF+RBV (12W) | 98.3/90.9 | Lawitz et al. 2013 [21] |
| G2 experience | 2.0 | 50.0 | PEGINF+RBV (48W) | 35.0/35.0 | Lagging et al. 2013 [37] | SOF+RBV (12W) | 91.0/87.5 | Zeuzem et al. 2013 [38] |
| G2 PEGINF ineligible | 2.9 | 40.0 | None | 0/0 | – | SOF+RBV (12W) | 91.8/93.3 | Jacobson et al. 2013 [17] |
| G2 naive coinfected | 0.4 | 40.0 | PEGINF+RBV (48W) | 86.0/61.1 | Labarga et al. 2012 [39] | SOF+RBV (12W) | 88.0/100.0 | Lalezary et al. 2013 [33] |
| G2 experienced coinfected | 0.4 | 50.0 | PEGINF+RBV (48W) | 86.0/61.1 | Labarga et al. 2012 [39] | SOF+RBV (12W) | 92.3/100.0 | Lalezary et al. 2013 [33] |
| G3 naive | 7.2 | 40.0 | PEGINF+RBV (24W) | 71.2/29.7 | Lawitz et al. 2013 [21] | SOF+ PEGINF + RBV (12W) | 100.0/83.3 | Lawitz et al. 2013 [40] |
| G3 experienced | 4.7 | 50.0 | PEGINF+RBV (48W) | 35.0/35.0 | Lagging et al. 2013 [37] | SOF+ PEGINF + RBV (12W) | 83.8/83.3 | Lawitz et al. 2013 [40] |
| G3 ineligible PEGINF | 6.2 | 40.0 | None | 0/0 | – | SOF+RBV (24W) | 85.0/60.0 | Zeuzem et al. 2013 [38] |
| G3 experienced coinfected | 0.5 | 50.0 | PEGINF+RBV (48W) | 86.0/61.1 | Labarga et al. 2012 [39] | SOF+RBV (24W) | 100.0/80.0 | Sulkowski et al. 2013 [36] |
| G4/5/6 naive | 11.6 | 40.0 | PEGINF+RBV (48W) | 50.0/38.6 | Manns et al. 2001 | SOF + PEGINF+ RBV (12W) | 100.0/50.0 | Lawitz et al. 2013 [20] |
W: Weeks, G: Genotype, PEGINF: pegylated interferons, RBV: ribavirine, SOF: sofosbuvir.